Global Diabetes Associated Ophthalmic Treatment Market Insights Forecasts to 2033

• The Global Diabetes Associated Ophthalmic Treatment Market Size was Valued at USD 29.75 Billion in 2023
• The Market Size is Growing at a CAGR of 6.61% from 2023 to 2033
• The Worldwide Diabetes Associated Ophthalmic Treatment Market Size is Expected to Reach USD 56.43 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Diabetes Associated Ophthalmic Treatment Market Size is Anticipated to Exceed USD 56.43 Billion by 2033, Growing at a CAGR of 6.61% from 2023 to 2033.

Market Overview

Diabetes mellitus is a metabolic disorder characterized by excessively high levels of blood sugar called hyperglycemia. Elevated blood sugar levels are the main reason for disease conditions such as peripheral neuropathy, diabetic ketoacidosis, diabetic retinopathy, cardiovascular diseases, etc. This includes diabetic retinopathy which is a medical condition that results from diabetes and often causes blurred vision and blindness in running age groups The condition arises when diabetes damages the tiny blood vessels in the retina which is the soft tissue at the back of the eye. Common treatments for diabetic eyes are anti-VEGF (Vascular Endothelial Growth Factor) injections, laser treatments, and cataract surgery. These treatments depend on the severity of the medical condition. Moderate or mild diabetes requires lifestyle changes such as sugar reduction, exercise, and meditation to slow the progression, and for advanced cases, the above treatment and the methods. As per the data provided by the Centers for Disease Control and Prevention diabetes affected 38.4 million persons of all ages, or 11.6% of the total population in the United States for the year 2021.

Report Coverage

This research report categorizes the market for the diabetes associated ophthalmic treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the diabetes-associated ophthalmic treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the diabetes associated ophthalmic treatment market.

Driving Factors

The increasing prevalence of type 2 diabetes, the aging population, and the availability of early detection methods are growth factors This is coupled with increasing knowledge on early detection and technological developments to help improve existing treatments. A growing number of clinical trials to evaluate new medications and technology for the prevention and treatment of various diabetes-related ocular disorders are projected to drive market expansion in the future years.

Restraining Factors

Treatments and procedures such as laser surgery and injections can cause dry eyes, redness, and vision problems. Some medications involve frequent injections or surgeries that can be uncomfortable and stressful for patients. Also, the therapies can be costly as the doctors frequently call for repeated surgeries and long-term follow-up, which can be a financial strain also the treatments may not fully restore vision or stop the progression of an illness.

Market Segmentation

The diabetes associated ophthalmic treatment market share is classified into type, application and end-use.

• The drug segment is expected to hold the largest share of the diabetes associated ophthalmic treatment market during the forecast period.   

Based on the type, the diabetes associated ophthalmic treatment market is categorized into devices and drugs. Among these, the drugs segment is expected to hold the largest share of the diabetes associated ophthalmic treatment market during the forecast period. Drugs used in the treatment of diabetes induced eyes medical condition are Anti-VEGF (vascular endothelial increase thing) marketers like ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin) that reduces the swelling of the macula part of the retina located in the back of the eye and slows down the vision loss, steroid medicines, and hypolipidemic agent. Also, the release of New Medical Entities (NMEs) or tablets that improve the efficacy and safety of cures for diabetic eye issues is largely due to ongoing studies and improvement efforts within the field of diabetic ophthalmic remedies.

• The diabetic retinopathy segment is expected to grow at the fastest CAGR during the forecast period.   

Based on the application, the diabetes-associated ophthalmic treatment market is categorized into glaucoma, diabetic retinopathy, eye allergy & infection, dry eye syndrome, diabetic-associated macular degeneration, cataracts, and uveitis. Among these, the diabetic retinopathy segment is expected to grow at the fastest CAGR during the forecast period. Diabetic retinopathy causes blurred vision and blindness in active people. Various therapies and procedures such as anti-VEGF injections, steroid drugs, focal laser therapy, and vitrectomy are commonly used for diabetic retinopathy Furthermore, an increasing number of clinical trials have approved drug treatments for diabetic retinopathy and is expected to speed up the market expansion of diabetes related ophthalmic products.

• The hospital segment is expected to grow at the fastest CAGR during the forecast period.   

Based on the end-user, the diabetes-associated ophthalmic treatment market is categorized into ambulatory surgical centers, hospitals, and ophthalmic centers. Among these, the hospital segment is expected to grow at the fastest CAGR during the forecast period. Extensive healthcare facilities offered by hospitals and an increasing number of treatments for diabetic patients contribute to the growth of this segment. Routine monitoring of the patient’s glycemic index, and implementation of a comprehensive treatment plan for the individual patient with diabetes. As per the data provided by the Centers for Disease Control and Prevention, the annual Hospital visit rate by adults with diabetes was 72.2 visits per 1,000 adults for the year 2021 in the United States.

Regional Segment Analysis of The Global Diabetes Associated Ophthalmic Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the diabetes associated ophthalmic treatment market over the forecast period.

North America is projected to hold the largest share of the diabetes associated ophthalmic treatment market over the forecast period. The region is associated with the availability of robust healthcare infrastructure, large investments in state-of-the-art medical infrastructure and equipment, and the increasing diagnosis of diabetes-related diseases. Furthermore, increased federal government investment in the healthcare sector in this area further encourages the development and access to new treatments. As per the data provided by the Centers for Medicare & Medical Services U.S. healthcare spending climbed 4.1 percent in 2022, hitting USD 4.5 trillion, or $13,493 per person.

Asia Pacific is expected to grow at the fastest CAGR growth of the diabetes associated ophthalmic treatment market during the forecast period. The aging population in many Asia Pacific countries greatly increases the incidence of diabetes, as older persons are more vulnerable to the ailment due to different age-related physiological changes and the accumulation of risk factors over time. An increased incidence of issues related to diabetes, such as diabetic retinopathy and diabetic macular edema, which call for specialized eye treatment is due to the demographic development in the healthcare sector.  As per the data provided by the United Nations Fund for Population Activities (UNFPA), the count of aging population in India was around 153 million in 2023.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Diabetes associated ophthalmic treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• F. Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.
• AbbVie Inc
• Novartis AG
• Quantel
• Pfizer, Inc.
• Ellex Medical Lasers Ltd.
• Bausch Health Companies Inc.
• Carl Zeiss Meditec
• Abbott Medical Optics
• Santen Pharmaceutical Co. Ltd.
• Genentech, Inc.
• Bayer AG
• Alcon
• Topcon Corp.
• IRIDEX Corp.
• Lumenis
• Others

Key Market Developments

• In March 2023, The Ontario government and members of the Ontario Association of Optometrists (OAO) approved a new four-year funding deal to provide high-quality access to eye care treatments.

• In January 2024, the Union Ministry of India of India inaugurated the brand-new, cutting-edge Sharp Sight Eye Hospital dedicated to providing quality eye care treatment.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global diabetes associated ophthalmic treatment market based on the below-mentioned segments: 

Global Diabetes Associated Ophthalmic Treatment Market, By Type

• Devices
• Drugs

Global Diabetes Associated Ophthalmic Treatment Market, By Application

• Glaucoma
• Diabetic Retinopathy
• Eye Allergy & Infection
• Dry Eye Syndrome
• Diabetic Associated Macular Degeneration
• Cataract
• Uveitis

Global Diabetes Associated Ophthalmic Treatment Market, By End-Use

• Ambulatory Surgical Centers
• Hospitals
• Ophthalmic Centers

Global Diabetes Associated Ophthalmic Treatment Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa